← SynDRA
GSK2578215A
SynDRA canonical compound SYN1266334 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | LRRK2 |
|---|
| Mechanism of action | leucine rich repeat kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- leucine rich repeat kinase inhibitor
Cross-references
Synonyms
- GSK 2578215A
- MFCD22665702
- Q641JSF42X
- 2-benzyloxy-5-(2-fluoro-4-pyridyl)-N-(3-pyridyl)benzamide
- BDBM50401284
- UNII-Q641JSF42X
- C24H18FN3O2
- WCIGMFCFPXZRMQ-UHFFFAOYSA-N
- itor GSK2578215A
- orb1305949
- SCHEMBL10321469
- SCHEMBL29430005
- SCHEMBL29430025
- BDBM482159
- GLXC-05797
- HMS3740I09
- HMS6018O05
- EX-A1118
- LRRK2 inhibitor GSK2578215A?
- s7664
- AKOS024458262
- LRRK2 inhib1285515-21-0
- CCG-268642
- CS-3516
- GSK2578215
- NCGC00370783-04
- NCGC00370783-06
- NCGC00370783-09
- NCGC00370783-10
- AC-35433
- AS-72347
- DA-33593
- HY-13237
- SY116005
- F50677
- G733400
- 2-(Benzyloxy)-5-(2-fluoro-4-pyridyl)-N-(3-pyridyl)benzamide
- gsk-2578215a
Look up GSK2578215A in the interactive SynDRA portal →